4 ms·
We're in a reactive mode now. Preventive care is the low-cost, high-benefit future. Novel diagnostics like this are an essential part of that future. I wish th
by tomkinstinch 12y ago
We're in a reactive mode now. Preventive care is the low-cost, high-benefit future. Novel diagnostics like this are an essential part of that future.
I wish the author would have cited the papers related to this work, if not inline then as a list of DOIs at the bottom.
- niels_olson 12y agoHere's barnstormer paper. Published in 2011, I heard the speaker in 2013, and I just started another hematopathology rotation and seems like every patient is getting screened for the six most common mutations. Even if we can't get a marrow aspirate, we can draw peripheral blood and see what's going on in the marrow. http://www.nejm.org/doi/full/10.1056/NEJMoa1013343 http://www.nejm.org/doi/full/10.1056/NEJMoa1013343 Now, that's not quite the same as what this article is claiming: that we can diagnose carcinoma in situ for solid organ tumors from extra-cellular DNA fragments floating around in peripheral blood, but this is what's clinically validated and fairly close mechanically: you might be sick aren't symptomatic yet. Let's draw some blood and see if you're really sick.